Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Harold Bays Added: 2 weeks ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once… View more
Author(s): Ruben Nogueiras Added: 1 month ago
ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease… View more
Author(s): Chim C Lang Added: 3 weeks ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more
Author(s): Harold Bays , Naveed Sattar , Lydia Alexander , et al Added: 1 year ago
The on-demand version of Advancements in Obesity Management (AOM) 2024 explores the intricate links between obesity and cardiovascular disease, providing key insights in evolving diagnostic and treatment strategies.This event, led by Course DirectorsDr Harold Bays (Louisville Metabolic and Atherosclerosis Research Centre, US) and Prof Naveed Sattar (University of Glasgow, UK) brings together a… View more
Author(s): Scott Harris Added: 1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more
Start date: Jun 12, 2024 End date: Jun 12, 2024
Radcliffe Cardiology is proud to announce a new one-day event, Advancements in Obesity Management (AOM). Explore the intricate links between obesity and cardiovascular disease, gaining key insights in evolving diagnostic and treatment strategies.Join us for this live one-day event on Wednesday 12 June 2024 to deepen your understanding of the multifaceted treatment of obesity and cardiovascular… View more
Author(s): Varun Sundaram Added: 1 month ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more
Author(s): Barry Borlaug Added: 4 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more
Author(s): Harriette Van Spall , Milton Packer Added: 7 months ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating… View more
Author(s): Subodh Verma Added: 7 months ago
AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).SELECT is a randomized, double-blind, placebo… View more